GSK 'schemed' FDA's drug-device approval pathway to deflect asthma inhaler generics, lawsuit claims

GSK’s perpetual asthma inhaler updates have kept generics makers chasing a moving target for more than half a century, and it’s patients who are being forced to foot the bill, a new lawsuit filed in a Missouri federal court contends.